Foghorn Therapeutics Inc
Research Foghorn Therapeutics Inc (FHTX) on Bullrun: market cap USD 402.19M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerFHTX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 402.19M
- Financial periodQ2 2026
- RevenueUSD 16.07M
- Net income-USD 7.19M
- Free cash flow-USD 17.89M
Valuation Snapshot
latest market cap is USD 402.19M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 30.91M | -USD 74.28M | -USD 86.15M | n/a | -1.18 | USD 80.88M | USD 41.27M | -USD 108.50M |
| FY2024 | USD 22.60M | -USD 86.62M | -USD 101.31M | n/a | -1.58 | USD 55.45M | USD 37.13M | -USD 45.53M |
| FY2023 | USD 34.16M | -USD 98.43M | -USD 119.33M | n/a | -2.34 | USD 80.34M | USD 45.07M | -USD 77.19M |
| FY2022 | USD 19.23M | -USD 108.88M | USD 192.40M | n/a | -2.62 | USD 52.21M | USD 54.81M | USD 112.00K |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 402.19M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 305.95M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 262.40M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 272.30M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 266.70M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 944.52M | n/a | n/a | n/a |
About Foghorn Therapeutics Inc
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Foghorn Therapeutics Inc's market cap?
Foghorn Therapeutics Inc's market capitalization is USD 402.19M.
What does Foghorn Therapeutics Inc do?
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome.